Compare Essex Property Trust, Inc. (ESS) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Essex Property Trust, Inc. vs Heron Therapeutics Inc — how do they compare? Essex Property Trust, Inc. trades at $280.41 (market cap $18.15B), while Heron Therapeutics Inc trades at $0.33 (market cap $61.47M). The key difference: Essex Property Trust, Inc. is far larger — about 295.3× Heron Therapeutics Inc's market cap, and Essex Property Trust, Inc. pays a 3.93% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ESS | HRTX | |
|---|---|---|
Market Cap | $18.15B | $61.47M |
Sector | Real Estate | Health |
52-Week High | $298.33 | $1.49 |
52-Week Low | $239.61 | $0.32 |
Enterprise Value | $24.75B | $168.21M |
Dividend Yield | 3.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ESS trades at $282.11, down 0.39% on the day, with a bearish technical signal from moving averages and oscillators. The company reported Q2 2026 EPS of $0.97, missing expectations, but raised full-year guidance after strong property NOI growth. Revenue reached $1.89B in 2025 with a net income margin of 35.48%, though profitability is trending lower in 2026. Recent news includes ESS being named a top GreenTech company and signing a 500 MWh energy storage agreement with Juniper Energy.
The outlook is mixed: raised guidance and institutional buying support upside, but technical weakness and earnings miss pose near-term risks. Valuation ratios like P/E of 19.9 and P/S of 9.05 are reasonable for a REIT, yet debt levels and regional market volatility require caution. Analyst consensus is a Moderate Buy with a $305.86 price target, suggesting 8.4% potential upside from current levels.
HRTX trades at $0.3152, down 4.54% today, amid bearish technical signals and mixed earnings. The stock shows a high gross margin of 70.07% but negative net income margins, with Q2 2026 missing revenue and EPS estimates. Recent news highlights patent litigation developments and quarterly results falling short of expectations, contributing to investor caution.
The outlook remains challenged by persistent losses and operational cash burn, though analyst consensus is strongly bullish with 94.74% buy ratings. Key risks include execution on product sales, competitive pressures, and reliance on financing activities to sustain operations amid negative profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
